Start-ups Meet Pharma 2022

Start-ups Meet Pharma 2022

The Start-ups Meet Pharma is a challenge-based acceleration program focused on selecting the most promising health start-ups and scale-ups matching the corporate partners’ innovation needs, to deliver solutions that address quality and affordable healthcare for European patients. In 2022, we are enabling unparalleled exposure to industry executives and decision-makers at Novartis,  Boehringer Ingelheim, Sintetica and Takeda through one-to-one pitch sessions, support, value proposition development and partnership exploration.

If you are developing innovative technologies and services representing potential solutions for the selected challenges for 2022, submit your application now!

Programme structure

  • Module 1 “Meet and Learn” (2-6/05/2022, Online): Up to 15 workshops by top-notch speakers on different tools and methods to successfully build your company.
  • Module 2 “Meet and Pitch” (07-17/06/2022, Online): Up to 5-hour of workshops by pharma partners on how to collaborate with big players in the market and 1-on-1 pitch sessions.
  • Module 3 “Meet and Visit” (4-8/07/2022, Online/pharma companies’ premises): Up to 2-hour visit to the premises of the pharma partners and meeting internal decision-makers to discuss collaboration opportunities.
  • Module 4 “Meet and Win” (September 2022): 15 minutes pitch in front of external pharma company representatives and for some extra visibility.

What will you get?

  • One-on-one access to industry executives through pitch sessions, value proposition development and partnership exploration.
  • Personalized coaching to help you develop your entrepreneurial, business and pitching skills.
  • Corporate insights on how leading pharma companies make innovation work for their organisations.
  • Increase awareness of your start-up´s solution among decision-makers from European pharma companies.

By loading the video, you agree to YouTube’s privacy policy.
Learn more

Load video

Previous sponsors

Challenge #1

The global prevalence of Chronic Kidney disease is around 9% and is often underrecognized by patients and clinicians. Diagnosis, staging and appropriate referral of CKD patients by primary care physicians are important elements in reducing the burden of the disease. Boehringer Ingelheim is looking for a digital diagnostic support tool that aids the diagnosis of new CKD patients; flags the unrecognized CKD patients – especially those with high risk for progression; and could be integrated with the daily workflow of GPs.

Challenge #2

People living with rare diseases are often faced with challenges to obtain a correct diagnosis, and hence treatment. Takeda calls for digital health solutions that could improve or optimize the care and referral pathway for people with rare diseases to gain access to relevant laboratory testing to enable diagnosis and treatment decisions. There is a particular interest for solutions that could be applied to improve testing for Thrombotic thrombocytopenic purpura (TTP), which is an ultra-rare, life-threatening blood disorder.

Challenge #3

Sintetica is looking for innovative solutions in pain management, related to chronic pain but also to pain treatment in general, that could improve patients’ lives. These solutions could include but are not limited to: new types of pharmacological treatment, novel drug delivery routes, medical devices, digital approaches. There is a particular interest in the field of neuromodulation which is an expanding area of pain medicine that incorporates an array of non-invasive, minimally invasive, and surgical electrical therapies.

Challenge #4

Novartis is looking for a proven solution or platform that can support integrated care pathway (screening & diagnosis / identify patient, automate referral, treatment activation and follow-up) including any digital health interventions (e.g., behavior change / psychosocial aid/adherence) to optimize patient outcome (QoL, morbidity/mortality, productivity), reduce disease burden and minimize avoidable human resource utilization.


Interested start-ups are kindly invited to participate in our upcoming webinars aimed to provide a detailed overview of the programme, its timeline, and the application process.

  • 9 February 2022, 11:00 AM CET (Register here)
  • 9 March 2022, 11:00 AM CET (Register here)

Looking back at Startups Meet Pharma 2021: 5 challenges | 5 partners | 18 start-ups

In 2021 we partnered with five pharma companies: Abbott, Takeda, Merck, Amgen and AstraZeneca, to jointly organize the Start-ups Meet Pharma programme. During the programme, we have selected 18 start-ups that address the challenges pharma companies face with operational products and services. In 2021 the programme resulted in 4 NDAs signed, 3 pilot projects and 2 R&D projects in development.

Looking back at Startups Meet Pharma 2020: 5 challenges | 4 partners | 16 start-ups

In 2020, five challenges were released in collaboration with four EIT Health Partners: Amgen, Bayer, Beiersdorf and Boehringer Ingelheim. Over the course of 6 months, 16 start-ups from 15 different countries worked intensely with our key pharma partners over workshops, trainings, and 1-on-1 meetings. The results: 3 signed NDAs, 4 pilots currently in the planning phase, with their kick-off foreseen for early 2021, 2 applications to the EIT Health investor network and an open invitation for further engagement.

Startups Meet Pharma 2019 | 5 challenges | 5 partners | 14 start-ups

In the 2019 edition of the Startups Meet Pharma programme, startups that were developing digital solutions with an impact on both the pharmaceutical industry and patients were invited to tackle five challenges by Bayer, UCB, Johnson & Johnson, Amgen and Ferrer. Find out more about the programme and read more about Pilloxa’s experience in SMP 2019 in the interview with the founder and CEO, Francesco Mazzotta.


By loading the video, you agree to YouTube’s privacy policy.
Learn more

Load video


Bojana Trajkovska

Entrepreneurship Lead
+49 163 92 61 073